Novo Nordisk Faces New Legal Challenges Over Ozempic's Link to Irreversible Eye Condition
Event summary
- Parker Waichman LLP filed lawsuits on behalf of Georgia and California residents who developed NAION after taking Ozempic.
- The lawsuits were filed on June 29, 2026 (Precup v. Novo Nordisk Inc.) and June 30, 2026 (Grant v. Novo Nordisk, Inc.).
- Studies from JAMA Ophthalmology and Harvard's Mass Eye and Ear Institute show a significant link between semaglutide and NAION.
- Novo Nordisk continues to downplay the risks despite growing evidence.
The big picture
Novo Nordisk faces mounting legal and regulatory scrutiny over its blockbuster weight-loss drug Ozempic, as new studies confirm a link to NAION, an irreversible eye condition. The lawsuits highlight the growing tension between pharmaceutical innovation and patient safety, particularly as GLP-1 receptor agonists surge in popularity for weight loss. The strategic anomaly here is Novo Nordisk's continued downplaying of risks despite compelling scientific evidence.
What we're watching
- Regulatory Headwinds
- How regulatory bodies will respond to the growing evidence linking Ozempic to NAION.
- Legal Exposure
- Whether Novo Nordisk can sustain its current stance amid increasing lawsuits and scientific findings.
- Market Impact
- The pace at which these legal challenges could affect Ozempic's market share and revenue.
Related topics